politics
Supreme Court Temporarily Restores Mifepristone Access in Louisiana Case
The Supreme Court issued an emergency stay restoring nationwide mail and pharmacy access to the abortion pill mifepristone, following a Fifth Circuit ruling that restricted it. The case, brought by Louisiana, centers on standing issues and could force the Trump administration to clarify its position. Legal experts anticipate the dispute may extend into the midterm election season.
NewsweekAudio version
Tap play to generate a narrated version.
The U.S. Supreme Court on Monday temporarily restored broad access to mifepristone, the abortion pill, by issuing an emergency stay against a lower court ruling that had eliminated mail and pharmacy distribution nationwide. The decision came three days after a Fifth Circuit panel imposed the restrictions on May 1.
Briefs in the case are due May 7, with the justices set to consider competing applications from Louisiana and the drug's manufacturers. This marks the second time in recent years the Supreme Court has addressed challenges to FDA regulations on mifepristone.
In a 2024 ruling, the court unanimously dismissed a similar challenge on standing grounds, finding plaintiffs lacked a direct connection to the regulations.
Louisiana argues it has standing due to a 'sovereign injury,' claiming mailed pills undermine its ability to enforce its abortion ban. Legal experts, however, suggest this theory may face skepticism similar to the 2024 case. She noted it relies on potential Medicaid reimbursements for treating patients who have taken mifepristone, which is further removed from direct injury.
The case places the Trump administration in a difficult position, requiring the Justice Department to decide whether to defend the FDA's regulations on the merits or take a procedural stance that allows the restrictions to stand. Anti-abortion groups have expressed impatience with the administration's slow review of the drug, announced in September 2025.
Mary Ziegler, a constitutional law professor at the University of California, Davis, told Newsweek that conservative states are taking matters into their own hands due to the administration's delays. She predicted the case could drag on, keeping abortion issues prominent through the midterm elections.
Polling data indicates broad opposition to nationwide restrictions on mifepristone. Two KFF surveys from late 2025 found about two-thirds of Americans oppose a ban, while a Gallup poll in May 2025 showed 51 percent identifying as pro-choice, with a significant gender gap.
